| Identification | Back Directory | [Name]
BTdCPU | [CAS]
1257423-87-2 | [Synonyms]
BTdCPU
eIF2–GTP–tRNAiMetTernaryCompInhib, BTdCPU
Urea, N-1,2,3-benzothiadiazol-6-yl-N'-(3,4-dichlorophenyl)- | [Molecular Formula]
C13H8Cl2N4OS | [MOL File]
1257423-87-2.mol | [Molecular Weight]
339.2 |
| Chemical Properties | Back Directory | [density ]
1.664±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
DMSO: ≥ 250 mg/mL (737.03 mM) | [form ]
Solid | [pka]
11.75±0.43(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
BTdCPU is a potent heme regulated inhibitor kinase (HRI) activator that promotes eIF2α phosphorylation and induces apoptosis in Dexamethasone.html" class="link-product" target="_blank">Dexamethasone (HY-14648) (Dex)-resistant cancer cells. BTdCPU can be used in the study of cancers such as multiple myeloma and Dex-resistant multiple myeloma[1][2]. | [in vivo]
BTdCPU (175 mg/kg; i.p.; single daily for 21 days) inhibits tumor growth without toxicity in mice xenograft breast tumors model[2]. | Animal Model: | Female nude mice (mice xenograft breast tumors model)[2]. | | Dosage: | 175 mg/kg | | Administration: | Intraperitoneal injection; single daily for 21 days | | Result: | Led to complete tumor stasis,which persisted for the remainder of the 3-week study
Showed good safety in mice.
|
| [storage]
Store at -20°C | [References]
[1] Burwick N, et al. The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma. Leuk Res. 2017 Apr;55:23-32. DOI:10.1016/j.leukres.2017.01.007
[2] Chen T, et al. Chemical genetics identify eIF2α kinase heme-regulated inhibitor as an anticancer target. Nat Chem Biol. 2011 Jul 17;7(9):610-6. DOI:10.1038/nchembio.613 |
|
| Company Name: |
Syntechem Co.,Ltd.
|
| Tel: |
519-88298820 15861130028 |
| Website: |
http://www.syntechem.com |
|